A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC

In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.View the activity here